Modifying inhibitor specificity for homologous enzymes by machine learning
The FEBS Journal · 2026
DOI: 10.1111/febs.70249 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2026. Verfasst von Dor S Gozlan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Hauptthemen laut MEDLINE: Machine Learning, Matrix Metalloproteinase Inhibitors, Tissue Inhibitor of Metalloproteinase-2. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States-Israel Binational Science Foundation, Rosetrees Trust, Israel Cancer Research Fund.
Abstract (Originalsprache)
Selective inhibitors are essential for targeted therapeutics and for probing enzyme functions in various biological systems. The two main challenges in identifying such protein‐based inhibitors lie in the extensive experimental effort required, including the generation of large libraries, and in tailoring the selectivity of inhibitors to enzymes with homologous structures. To address these challenges, machine learning (ML) is being used to improve protein design by training on targeted libraries and identifying key interface mutations that enhance affinity and specificity. However, such ML‐based methods are limited by inaccurate energy calculations and difficulties in predicting the structural impacts of multiple mutations. Here, we present an ML‐based method that leverages HTS data to streamline the design of selective protease inhibitors. To demonstrate its utility, we applied our new method to find inhibitors of matrix metalloproteinases (MMPs), a family of homologous proteases involved in both physiological and pathological processes. By training ML models on binding data for three MMPs (MMP‐1, MMP‐3, and MMP‐9), we successfully designed a novel N‐TIMP2 variant with a differential specificity profile, namely, high affinity for MMP‐9, moderate affinity for MMP‐3, and low affinity for MMP‐1. Our experimental validation showed that this novel variant exhibited a significant specificity shift and enhanced selectivity compared with wild‐type N‐TIMP2. Through molecular modeling and energy minimization, we obtained structural insights into the variant's enhanced selectivity. Our findings highlight the power of ML‐based methods to reduce experimental workloads, facilitate the rational design of selective inhibitors, and advance the understanding of specific inhibitor–enzyme interactions in homologous enzyme systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
- Department of Computer Science, Bar-Ilan University, Ramat Gan, Israel.
- Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL, USA.
- The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
- National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
ORCID-Profile: Dor S Gozlan, Evette S Radisky, Yaron Orenstein, Niv Papo
Förderung
- United States-Israel Binational Science Foundation
- Rosetrees Trust
- Israel Cancer Research Fund
- Worldwide Cancer Research
Zitieren
APA
Gozlan, D. S., Meiri, R., Shapira, G., Coban, M., Radisky, E. S., Orenstein, Y., & Papo, N. (2026). Modifying inhibitor specificity for homologous enzymes by machine learning. The FEBS Journal. https://doi.org/10.1111/febs.70249
Vancouver
Gozlan DS, Meiri R, Shapira G, Coban M, Radisky ES, Orenstein Y, et al. Modifying inhibitor specificity for homologous enzymes by machine learning. The FEBS Journal. 2026. doi:10.1111/febs.70249
BibTeX
@article{Gozlan2026,
author = {Gozlan, Dor S and Meiri, Reut and Shapira, Gili and Coban, Matt and Radisky, Evette S and Orenstein, Yaron and Papo, Niv},
title = {Modifying inhibitor specificity for homologous enzymes by machine learning},
journal = {The FEBS Journal},
year = {2026},
doi = {10.1111/febs.70249}
}
EUVIMED